✦ LIBER ✦

Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival

✍ Scribed by Andreas Obermair; Elisabeth Kucera; Klaus Mayerhofer; Paul Speiser; Michael Seifert; Klaus Czerwenka; Alexandra Kaider; Sepp Leodolter; Christian Kainz; Robert Zeillinger

Publisher: John Wiley and Sons
Year: 1997
Tongue: French
Weight: 60 KB
Volume: 74
Category: Article
ISSN: 0020-7136
DOI: 10.1002/(sici)1097-0215(19970822)74:4<455::aid-ijc17>3.0.co;2-8

No coin nor oath required. For personal study only.

✦ Synopsis

Studies have shown that microvessel density influences breast-cancer prognosis. Since tumor angiogenesis is considered to be substantially affected by the excretion of vascular endothelial growth factor (VEGF) from tumor cells, we examined whether VEGF concentration is different in malignant and in non-malignant breast tissue. It was also of interest to discover whether intratumoral VEGF concentration influences disease-free survival (DFS) of breast-cancer patients. Analysis is based on 120 tissue specimens taken from breast fibromas (n = 23), normal epithelial breast tissue adjacent to fibromas (n = 8) and invasive breast cancer (n = 89). VEGF concentration was quantified by using an immunoassay. Microvessel density was determined by immunostaining for factor-VIII-related antigen. Median VEGF concentration is given in pg/mg protein (25%-quantile-75%-quantile) and it was 0 (0-1.8) in normal breast tissue, 9.8 (0.52-43.0) in fibromas and 130.4 (50.8-362.2) in invasive carcinomas. A univariate Cox model revealed that node status, tumor size, estrogen-receptor concentration, histological grading and microvessel density were prognostic factors for disease-free survival in breast cancer. We found a significant correlation between VEGF concentration and microvessel count, but VEGF concentration did not significantly influence disease-free survival. Although VEGF protein was found at a significantly higher concentration in malignant than in non-malignant tissue, determination of intratumoral VEGF protein by an enzyme immunoassay was not prognostically relevant in our patient population.

📜 SIMILAR VOLUMES

Plasma levels of vascular endothelial gr

Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, flt-1, in haematological cancers: A comparison with breast cancer

✍ Funmi M. Belgore; Gregory Y. H. Lip; David Bareford; Martin Wadley; Paul Stonela 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 29 KB 👁 2 views

Raised plasma VEGF is found in some cancers but levels of its receptor soluble Flt-1 (sFlt-1) are unreported. Hypothesising increased levels to be present in haematological cancers, we measured both by ELISA in 22 patients with haematological cancer, 22 with breast cancer, and in age-and sex-matched

p53 and vascular-endothelial-growth-fact

p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma

✍ Barbro Linderholm; Birgitta Lindh; Björn Tavelin; Kjell Grankvist; Roger Henriks 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 169 KB 👁 1 views

The angiogenic factor vascular endothelial growth factor (VEGF) predicts outcome in primary breast carcinoma. Alteration of the p53 gene causes down-regulation of the expression of thrombospondin-1, a natural inhibitor of angiogenesis. This study was conducted to investigate the association between

Vascular endothelial growth factor and i

Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer

✍ Dagmar Strohmeyer; Christian Rössing; Anja Bauerfeind; Olaf Kaufmann; Horst Schl 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 474 KB 👁 2 views

Vascular endothelial growth factor expre

Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma

✍ Kiyoshi Maeda; Soon-Myoung Kang; Naoyoshi Onoda; Masafumi Ogawa; Yasuyuki Kato; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB 👁 2 views

Recently many studies have demonstrated that the degree of tumor angiogenesis is related to the aggressiveness of the tumor and clinical outcome. Vascular endothelial growth factor (VEGF) is a well characterized inducer of angiogenesis. In this study, the authors investigated the prognostic signifi

Expression of vascular endothelial growt

Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival

✍ Decaussin, Myriam; Sartelet, Herv�; Robert, Catherine; Moro, Denis; Claraz, Chri 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 2 views

The formation of new vessels (angiogenesis) is essential for primary tumour growth and metastasis and is induced by several angiogenic factors, including vascular endothelial growth factor (VEGF). The microvascular density (MVD) in tumours was assessed and the expression of VEGF and its receptors VE

High pre-treatment serum level of vascul

High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer

✍ Petri Salven; Tarja Ruotsalainen; Karin Mattson; Heikki Joensuu 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 68 KB 👁 1 views

Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis and vascular permeability. Increased serum VEGF concentrations (S-VEGF) have been found in patients with various types of human cancer, including cancer of the lung. However, the clinical and prognostic significance